China: devices sector eases restrictions to lure foreign firms
This article was originally published in Clinica
Executive Summary
A major attraction for medical device manufacturers targeting the Chinese market is that 15% of the medical equipment in 175,000 domestic hospitals and clinics were made some 30 years ago and are in serious need of updating. This was the view of Mr Pan Yu Cheng, chief editor of China Medical Equipment Information, revealed at Medica, the world's largest medical device trade fair, in Dusseldorf, Germany, last year. In order to upgrade some 13,000 hospitals above county level to the standard that Japanese hospitals achieved in 1980 - a cost of $96,000 per 100 beds - would cost some $144-180m. It is also a priority for China to see that its less developed, rural areas are properly equipped.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.